Sept 25 (Reuters) - NPS Pharmaceuticals Inc said its partner GlaxoSmithKline decided to prematurely stop a mid-stage study of an osteoporosis drug that was being developed under a collaboration agreement between the firms, sending its shares down more than 15 percent.
